Company

Biodexa Pharmaceuticals PLC

Biotechnology Research United Kingdom 22 employees BDRX

Employees: 22
Contacts: 2
Emails: 2
Phones: 1

midatechgroup.com LinkedIn

Biodexa Pharmaceuticals PLC Overview

Headquarters: United Kingdom
Website: midatechgroup.com
Industry: Biotechnology Research
Employees: 22
Founded: 2000
Stock Symbol: BDRX
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

About Biodexa Pharmaceuticals PLC

Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain. The Company’s lead candidate, MTX110, is being studied in aggressive rare/orphan brain cancer indications including recurrent glioblastoma and diffuse midline glioma. MTX110 is a solubilised formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour, by-passing the blood-brain barrier and avoiding systemic toxicity.

Biodexa Pharmaceuticals PLC Contact Details

People in AeroLeads: 4
With contact data: 2
Email contacts: 2; 50.0% coverage
Phone contacts: 1; 25.0% coverage

Biodexa Pharmaceuticals PLC Org Chart

Sample employees and titles

Name	Title	Location	Contact
Simon Turton		Easton Royal, England, United Kingdom	Email Phone
Sara Siddall	Senior Finance & Administration Manager	Greater Cardiff Area, United Kingdom	Email
Ann Merchant	Board Member at Alvotech Sa and Biodexa		View
Steve Ellul			View